Gene suppressing therapy for Pelizaeus-Merzbacher disease using artificial microRNA

Area of Science:

• Genetics
• Neuroscience
• Molecular Biology

Background:

• Genomic disorders arise from copy number variations in dosage-sensitive genes.
• Pelizaeus-Merzbacher disease (PMD), an X-linked hypomyelinating leukodystrophy, is often caused by PLP1 gene duplication.
• PLP1 overexpression is the suspected primary cause of PMD's severe hypomyelination.

Purpose of the Study:

• To investigate adeno-associated virus (AAV)-mediated gene suppression as a therapeutic strategy for PMD.
• To develop an oligodendrocyte-specific gene therapy targeting PLP1 using artificial microRNA delivered via scAAV.
• To assess the efficacy of this therapy in correcting gene product aberrations and improving disease phenotypes.

Main Methods:

• Developed an oligodendrocyte-specific Plp1 gene suppression therapy using artificial microRNA on an scAAV platform.
• Administered a single direct brain injection of the AAV vector in wild-type (WT) and Plp1-transgenic mice.
• Evaluated Plp1 suppression, oligodendrocyte preservation, myelin structure, gene expression, survival, and neurological phenotypes.

Main Results:

• Achieved widespread, oligodendrocyte-specific Plp1 suppression in the white matter of WT mice.
• In Plp1-transgenic mice, AAV treatment reduced cytoplasmic Plp1 accumulation and prevented oligodendrocyte degradation.
• Restored myelin structure and gene expression, leading to improved survival and neurological outcomes.

Conclusions:

• AAV-mediated gene suppression therapy shows promise as a potential cure for PMD caused by PLP1 duplication.
• This approach may also be applicable to other genomic disorders characterized by gene copy number variations.
• The study highlights the therapeutic potential of targeted gene suppression in treating complex genetic neurological diseases.